Glucose as a modifiable cause of atherosclerotic cardiovascular disease: insights from type 1 diabetes and transplantation
NON-STIMULANT: Unlike many fat burners, BPI Sports CLA + Carnitine contains no stimulants
Why We Prefer Tesamorelin: FDA-approved for reducing visceral fat in HIV-associated lipodystrophy Mimics natural GHRH without a DAC Well-studied in clinical trials More effective at raising GH and IGF-1 levels Safer, with a cleaner side effect profile Superior for metabolic health and body composition You can also learn more about our Tesamorelin + Ipamorelin combo peptide
In addition to JPH-203, other drugs currently in preclinical and clinical trials targeting LAT1 include IPA-131, QBS-10072S, TLX101-CDx, 124I-ACD-101, 211At-TLX-102, OKY-034, [18F] NKO-028 (Table 1)
If you are considering these medications, I highly encourage you to not just rely on the prescription pad